

# Nicole McCarthy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1146496/publications.pdf>

Version: 2024-02-01

17  
papers

912  
citations

1040056

9  
h-index

1058476

14  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1307  
citing authors

#	ARTICLE	IF	CITATIONS
1	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	1.6	153
2	Effect of a Remotely Delivered Weight Loss Intervention in Early-Stage Breast Cancer: Randomized Controlled Trial. <i>Nutrients</i> , 2021, 13, 4091.	4.1	16
3	Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 3-11.	1.1	4
4	Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-negative amplified metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 12-21.	1.1	1
5	Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. <i>Clinical Breast Cancer</i> , 2017, 17, 139-153.	2.4	3
6	The Living Well after Breast Cancer, Pilot Trial: a weight loss intervention for women following treatment for breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 125-136.	1.1	39
7	Living well after breast cancer randomized controlled trial protocol: evaluating a telephone-delivered weight loss intervention versus usual care in women following treatment for breast cancer. <i>BMC Cancer</i> , 2016, 16, 830.	2.6	19
8	Final Survival Analysis of ROSE/TRIO-012. <i>Journal of Clinical Oncology</i> , 2016, 34, 3714-3715.	1.6	0
9	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 3-18.	1.1	8
10	Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 19-31.	1.1	2
11	Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 141-148.	1.6	113
12	Triple-negative breast cancer: making the most of a misnomer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 145-155.	1.1	9
13	TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 258-261.	2.4	28
14	Improving Informed Consent in Clinical Trials: Successful Piloting of a Decision Aid. <i>Journal of Clinical Oncology</i> , 2007, 25, 1443-1444.	1.6	15
15	Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 769-777.	1.6	502
16	Anastrozole. <i>Drugs</i> , 2002, 62, 2493-2494.	10.9	0
17	Perspectives in Post-Transplantation Immunotherapy in Breast Cancer. <i>Breast Disease</i> , 2001, 14, 69-79.	0.8	0